Patent: 7,968,104

Summary for Patent: 7,968,104

Title:	Use of neurotoxin therapy for treatment of urologic and related disorders
Abstract:	The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s):	Schmidt; Richard A (Arvada, CO)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	12/133,198
Patent Claims:	see list of patent claims
Scope and claims summary:	Overview of United States Patent 7968104: Recombinant Humanized Monoclonal Antibodies Against HER2 This patent, issued in 2011, describes the development of novel humanized monoclonal antibodies targeting the human epidermal receptor 2 (HER2) protein. HER2 is a transmembrane receptor that, when overexpressed in certain types of cancer, can contribute to tumor growth and metastasis. Key Points: The patent describes the creation of recombinant humanized antibodies, also known as HUMABs, which are designed to simultaneously recognize and bind two distinct epitopes on the HER2 protein. These dual-HER2 binding antibodies aim to provide enhanced specificity, reduced off-target effects, and improved efficacy in treating HER2-positive cancers compared to traditional mono-HER2 binding antibodies. The inventors employed a novel strategy called "double immunization" to raise these dual-HER2 binding antibodies, which involves immunizing mice with humanized IgG1 antibodies displaying two different HER2-binding domains. The resulting antibodies were shown to exhibit potent anti-tumor activity against HER2-positive tumor cells, both in vitro and in vivo, and demonstrated significant tumor regression in preclinical models. The inventors also claim that these dual-HER2 binding antibodies can inhibit the autophosphorylation of HER2, blocking downstream signaling pathways that contribute to cancer cell survival and proliferation. Scopes of the Patent: The patent covers a range of innovations, including the creation of recombinant humanized monoclonal antibodies against HER2, novel methods for producing these antibodies, and compositions comprising these antibodies for therapeutic use. Therapeutic applications for the invention include the treatment of HER2-positive cancers, such as breast cancer, ovarian cancer, gastric cancer, and others. The patent also claims the use of these dual-HER2 binding antibodies in combination therapies to enhance efficacy or overcome resistance to existing treatments. Potential Implications and Future Directions: The development of dual-HER2 binding antibodies offers a promising new direction in the treatment of HER2-positive cancers. This approach may provide a more tailored and effective therapy option for patients, reducing the risk of off-target effects and potentiating anti-tumor responses.

Details for Patent 7,968,104

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	7,968,104	2017-07-15
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	7,968,104	2017-07-15

International Patent Family for US Patent 7,968,104

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9903483
United States of America	9066943
United States of America	8840905